Banner - NPPA Connect

NP/PA Connect
News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|January 7, 2025

When to Consider Systemic Treatment for Prurigo Nodularis Patients

Author(s)TJ Chao, MPAS, PA-C

TJ Chao, MPAS, PA-C, discusses how systemic treatments for prurigo nodularis are considered for patients with moderate to severe disease, highlighting key patient-specific factors such as comorbidities and disease severity when initiating treatment.

Episodes in this series

EP. 1 Prurigo Nodularis Burden of Disease

EP. 1 Prurigo Nodularis Burden of Disease

EP. 2 Challenges in Diagnosing Prurigo Nodularis and Distinguishing From Other Pruritic Conditions

EP. 2 Challenges in Diagnosing Prurigo Nodularis and Distinguishing From Other Pruritic Conditions

EP. 3 New Systemic Treatments for Prurigo Nodularis

EP. 3 New Systemic Treatments for Prurigo Nodularis

EP. 4 Talking to Patients About Itch Management

EP. 4 Talking to Patients About Itch Management

EP. 5 Provider and Patient Considerations for Prurigo Nodularis Treatment

EP. 5 Provider and Patient Considerations for Prurigo Nodularis Treatment

EP. 6 The Burden of Prurigo Nodularis

EP. 7 Considerations for Setting Treatment Goals in Prurigo Nodularis

EP. 7 Considerations for Setting Treatment Goals in Prurigo Nodularis

EP. 8 New Systemic Treatment Options for Prurigo Nodularis

EP. 8 New Systemic Treatment Options for Prurigo Nodularis

EP. 9 A Rapidly Changing Landscape in Prurigo Nodularis Signals New Directions and Opportunities for Treatment

EP. 10 When to Consider Systemic Treatment for Prurigo Nodularis Patients

EP. 10 When to Consider Systemic Treatment for Prurigo Nodularis Patients

EP. 11 Educating Patients on Systemic Prurigo Nodularis Treatment and Adherence

EP. 11 Educating Patients on Systemic Prurigo Nodularis Treatment and Adherence

EP. 12 Key Takeaways for Prurigo Nodularis Treatment

EP. 12 Key Takeaways for Prurigo Nodularis Treatment

Video content above is prompted by the following:

For which type of patient would you consider systemic treatments for prurigo nodularis patients?

What patient-specific factors do you consider when starting treatment?

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

Tips for Managing Pain and Local Skin Reactions During Photodynamic Therapy

ByNeal Bhatia, MD,Kaitlyn Bader, Assistant Managing Editor

May 27th 2026

Field-Directed PDT May Improve Long-Term Management of Actinic Damage and Superficial BCC

ByNeal Bhatia, MD,Kaitlyn Bader, Assistant Managing Editor

May 20th 2026

Why Treating Beyond the Tumor Is the Key to Long-Term Skin Cancer Prevention

ByNeal Bhatia, MD,Kaitlyn Bader, Assistant Managing Editor

May 15th 2026

Treating the Field, Not Just the Tumor: PDT's Expanding Role in Superficial BCC

ByNeal Bhatia, MD,Kaitlyn Bader, Assistant Managing Editor

May 13th 2026

Post Hoc Analysis Shows Dupilumab Improves PAS Scores in Patients with Prurigo Nodularis

ByMarie Bosslett, Assistant Editor

April 17th 2026

Latest CME

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Trending on Dermatology Times

Dermalogica Enters Medical Aesthetics with FDA-Cleared Microneedling PRO Pen

Social Media Mythbusters: Hypochlorous Acid Sprays

Quoin Submits First-Ever IND Application for Peeling Skin Syndrome Therapy

Topical GX-03 Hits 92.6% EASI-50 at Week 4 in Phase 2 AD Interim

SkinJect Advances into Registrable Development as Potential First-in-Class Therapy for Gorlin Syndrome